Introduction
The management of prostate cancer is changing rapidly 1 and new agents such as abiraterone and MDV3100 are likely to alter the landscape, especially for those individuals with CRPC who have already received chemotherapy [2] [3] [4] [5] . Whilst locally advanced and metastatic cases are managed by androgen deprivation in the first instance, once this treatment fails the use of chemotherapy is usually considered. The most established therapy is with single agent docetaxel, following the demonstration that it was able to modestly prolong survival in two randomised phase 3 studies 6, 7 .
A number of other agents have been shown to be efficacious, in keeping with the long natural history of CRPC. Cabazitaxel has now been approved by the US FDA though many consider the toxicities unacceptable 8, 9 ; alkylating agents have also been used in the management of prostate cancer for many years although no effects on survival have been observed 10, 11 . In one phase 2 study of intravenous melphalan using 30mg/m 2 every 4 weeks in 27 patients, there were no objective responses although one quarter received more than 4 months of therapy due to overall disease stabilisation 12 . We have used chlorambucil based therapy in a large number of CRPC cases and have demonstrated disease stabilisation and importantly re-induction of hormone sensitivity ie. endocrine treatment (GNRH analogues, peripheral anti-androgens, corticosteroids and estrogens) failing prior to chemotherapy subsequently working in up to 40% of cases when patients were rechallenged following failure of chemotherapy 13 . Here, we hypothesised that more intensive chemotherapy would increase the number of patients achieving disease control and allow a greater number to benefit from this effect.
To study the effects of alkylating agents further, we have used melphalan as an option since it is not only suitable for dose intensification but also its short half-life means that it is suitable for hematologic support using unprocessed autologous whole blood from patients given high dose lenograstim to increase the number of CD34 positive progenitor cells. This has been demonstrated in myeloma , however in these cases the process has generally only been used to support a single high dose treatment and not multiple cycles 14 . In the management of small cell lung cancer and ovarian carcinoma such a process has also been used to support multiple cycles of carboplatin-based chemotherapy [15] [16] [17] .
We therefore investigated this approach in a dose finding study to observe whether lenograstim mobilized stem cells in whole blood could support multiple cycles of melphalan given every 2 weeks in the setting of CRPC. The dose of melphalan was escalated and
Research. unlike previous studies the stem cells were mobilised on each cycle using a short 4-5 day course of high dose lenograstim prior to venesection. This allowed fixed timing of venesection and administration of melphalan. To understand the effects of this therapy, as well as measuring PSA, we also analysed levels of CTCs prior to and during therapy 18 following convincing data for their utility in this setting including superior correlations with outcome compared with PSA measurements 19, 20 . Since we have previously demonstrated that we can identify individuals who are likely to have a prolonged survival within 1 month of commencing a new therapy 21 , we wished to see whether such an approach could be used here.
Research. 
Patients and Methods
The study aim was to determine the safety and efficacy of intensified intravenous melphalan with whole blood stem cell transplantation in patients with CRPC. The primary endpoint was to determine the dose limiting toxicity of the schedule. The efficacy endpoints were the PSA reduction rate, CTC response and whether re-induction of endocrine sensitivity occurred.( Quality of life (QoL) was assessed prior to treatment and at 2-weekly intervals for 8 weeks and then 1 month after the completion of chemotherapy. Computed tomography and isotope bone scanning was performed 12 weeks after the start of therapy.
The EORTC QLQ-C30 quality of life questionnaire together with prostate specific module QLQ-PR25 was used to measure five functional scales (physical, role, emotional cognitive, social), three symptom scales (fatigue, nausea and vomiting, pain), a global health status / QOL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). The study was approved by the local ethics committee.
All patients recruited had biopsy proven CRPC and evidence of tumor progression using the PCWG2 criteria 22 ; all were symptomatic and prior chemotherapy was not permitted.
Patients were required to have a ECOG performance status of 0-2, an unsupported hemoglobin of >110g/l, no contra-indication to large volume venesection (eg. active angina or heart failure) and a life expectancy of at least 12 weeks. Patients had pre-treatment investigations consisting of computed tomography of the chest, abdomen and pelvis, a bone scan, full laboratory investigations including LDH and in addition blood was drawn for CTCs as we have described 23, 24 . Lenograstim was administered at a dose of 10mcg/kg for 3 days. Initially patients went on to have chemotherapy regardless of the pre-chemotherapy CD34 count on the 4 th day, but after 2 patients failed to mobilise and were found to have low CD34 counts the protocol was modified such that patients who failed to have a CD34
count of >9/ L after 3 days of lenograstim were withdrawn from the study. Patients were recruited in cohorts of 3 and 6 dose levels were planned. The volume of blood venesected was dependent on patient's weight. Those patients weighing more than 80kg had 1000mL venesected and those weighing less had 750mL venesected. The blood was collected in a
Baxter blood donation bag with anticoagulant and refrigerated at 4°C. Intravenous melphalan was given over 15 mins and patient's had their autologous blood returned the following day at least 12 hrs after the melphalan (day zero). On day 9, lenograstim was restarted this time for 5 days. On day 15 (2 weeks after the previous cycle), if the complete blood count showed a neutrophil count of greater than 1 regardless of CD34 count, blood was venesected and the melphalan given. A total of 4 cycles given over 42 days was planned. Laboratory tests including CTCs were taken prior to each cycle of melphalan. 
PSA response
The maximal PSA response to melphalan alone is demonstrated in a waterfall plot ( Figure   2 ). Overall 16 (67%) had a fall in PSA and the nadir was reached at a median of 7 weeks (range 4-21 weeks) following the start of melphalan. Nine (38%) had at least a 30% reduction in PSA by 12 weeks. Overall, 12 patients (50%) had a 30% reduction in PSA and 10 (42%) had a 50% reduction in PSA. The median time for the PSA to reach its nadir was 54 days (range 3-152 days). The median time to progression based on PSA alone measured 2.8 months (95% CI 2.0-3.7) on melphalan.
Radiologic Response
Bone scans and computed tomography were repeated at 12 weeks and 23 patients were assessable for bone scan response. Four patients (17%) showed progressive disease using the PCWG2 criteria. In one patient this occurred despite a fall in CTC counts and relief of bone pain (this may have represented a pseudoprogression but he was lost to follow-up before a further scan could be arranged). Eleven patients were assessable for their soft tissue disease and of these 4 (36%) achieved a partial response and 7 (64%) had stable disease.
Circulating Tumor Cells
CTCs were measured in 16 patients. In 10 there were > 5/7.5mL. In 9 they fell to <5 within 6 weeks. Patients with raised CTCs had a numerical non-significant shorter progressionfree survival (5.7 vs 9.2 months, p=0.19) although median overall survival was similar (27 vs 30.6 months). Those patients who had raised numbers of CTCs at the start of therapy showed a rapid response. In 4 patients the CTC count fell to less than 5 after 1 cycle of melphalan (2 weeks after start of chemotherapy). These patients had a prolonged overall survival (30.6 months vs 15.3 months, p=0.034). At 4 weeks there was an association between CTC levels and PSA change. Those patients with raised CTC counts that had fallen to < 5/7.5ml ( 6 out of 10) had a median 36% fall in PSA (range 17% increase to 65% fall); those whose CTCs failed to come down to this level had a median 34% rise in PSA ( range 4% increase to 221%, p=0.033; Figure 3) . CTCs therefore were able to identify responding patients within 4 weeks of starting therapy, unlike PSA where changes showed greater variability.
Toxicity
Treatment was associated with significant toxicities (Table 3 ). There was 1 treatment related death (cohort 2) and the patient had received all 4 cycles of melphalan. On the third cycle he had significant neutropenic fever which resolved with neutrophil recovery. After the Seven patients failed to complete the protocol. In 2 this was because of failure to release stem cells following the initial lenograstim; both these patients received only 1 cycle of melphalan. In 1 patient there was prolonged neutropenia after 2 cycles, one stopped after 3 cycles following a florid drug reaction to ceftazidime (he was known to be penicillin sensitive). One patient had clear progression after 3 cycles, one stopped after persistent rapid atrial fibrillation whilst neutropenic, one stopped after significant septicemia on cycle 3. In all but the first 3 the blood count recovered to allow a fourth cycle had it been appropriate.
Re-challenge with previously failing endocrine agents
Hormone therapy was stopped during chemotherapy based on the theory that more cancer cells would be susceptible to chemotherapy. In addition, re-introduction of endocrine treatment often produces further responses. Following a subsequent PSA rise the hormones that had failed were re-introduced in 20 patients : maximal androgen blockade in all and dexamethasone with or without diethylstilbestrol in those who had been exposed to these prior to melphalan. Overall 7 responded with a > 50% reduction in PSA.
Dexamethasone was restarted in 9 patients and 4 responses occurred. Diethylstilbestrol was given to 6 patients prior to melphalan of whom 3 responded when re-challenged.
Overall 48% had a response to a hormone therapy that had failed prior to melphalan.
The time to failure for these re-introduced treatments measured 5.7 months (95% CI 4.2-1.0). Overall 48% responded to re-challenge with prior hormone therapy. The median overall survival for all patients in the study was 27 months (95% CI 16.2-not reached; interquartile range-17.6-32.6 months).
Quality of Life and Pain response
At the start of the study 80% of patients had pain due to their prostate cancer. There was a significant improvement in patients' pain scores within 2 weeks of the start of chemotherapy (p = 0.001) which was maintained throughout the study (see table 4) Fatigue and dyspnea increased after two cycles (4 weeks) compared to baseline (p = 0.009 and p = 0.004, respectively). These symptomatic scores correlated strongly with QoL globular scores.
Further therapy
Diethylstilbestrol was given to 6 patients who had not received it prior to melphalan, 4 responded for between 4-8 months. Sixteen went on to receive docetaxel without unexpected myelosupression. The median number of cycles given was 6 (range 2-6) with a 30% PSA response rate of 13 % and a median time to progression of 4.1 months (range 
Discussion
As the treatment of CRPC is evolving with the discovery that many individuals are not truly castrate or hormone refractory 1, 5 , we elected to use high dose chemotherapy to observe if this could be used as a treatment option. Following our recent data, we also wished to specifically observe whether changes in biomarkers (PSA or CTCs) at 1 month could predict survival 21 . We found that responses in patients with heavily pre-treated CRPC could be induced by our protocol, and that in those individuals with raised CTCs at the start of therapy, a rapid decrease was associated with a survival benefit. In the future this can be used to select those individuals more likely to respond, thus avoiding toxicities.
Furthermore, many individuals subsequently received further hormonal therapy and docetaxel.
The administration of melphalan and whole blood stem cell re-infusion was too toxic for routine use but we were able to deliver it with considerable support .It was possible to shown that whole blood progenitors will support multiple cycles of chemotherapy allowing dose density to be increased, this has never been shown previously with melphalan. The dose to take forward for a formal phase 2 study would appear to be the highest dose (it was not dose limiting), however the 4 th cycle was associated with prolonged platelet recovery and the median CD34 count had fallen prior to this cycle substantially therefore omitting would appear to have the advantage of decreasing toxicity (hospital admissions as well as blood product use) and further shorten the treatment.
Hematologic toxicity was considerable but was generally rapidly reversible and the use of compared to the standard 30 weeks for 10 cycles of docetaxel). In addition, it was possible to give docetaxel following therapy. The use of fixed periods of high dose lenograstim allowed predictable blood count recovery; to our knowledge this has not been previously demonstrated.
The rapid response in pain was very encouraging and it was impressive that a statistically significant improvement in pain occurred within 2 weeks of the start of treatment and that this was maintained, showing the efficacy for this therapy. The decision to stop hormone therapy during chemotherapy and only re-start in the face of progression was controversial but the subsequent response to hormone re-challenge was encouraging. It is interesting that although symptom response occurred early, PSA response was delayed and often the PSA decline did not start until after the treatment was completed.
The use of CTCs to monitor response to such an intensive treatment was clearly demonstrated and importantly this could be used early. Patients with <5 CTCs /7.5 mL had a numerically higher survival. Where CTCs were detected, reductions occurred rapidly with responses being seen within 2 weeks. These patients who showed this response also had numerically higher survival times. CTCs may be useful in future to help decide which patients should stop this therapy early as their changes were much more rapid than PSA. This supports our previous work in which we developed an easy-to-use prognostic index to identify those individuals with a prolonged survival within 1 month of starting therapy using PSA 21 , however in this case the use of intensive chemotherapy followed by re introduction of hormonal treatment made early changes in PSA much less useful .The principle of early identification of response to a therapy is of particular importance in managing CRPCwhere the number of options has expanded, allowing a change to an alternative and minimizing toxicity. In this intensive approach CTCs seemed particularly well suited whilst with hormone therapy PSA remains important again potentially allowing responding patients to be identified within 4 weeks of starting therapy. The decision to withdraw hormone therapy during this study was controversial, whilst it is not possible to say that re-induction of endocrine sensitivity occurred the response to re-challenge particularly with dexamethasone and diethylstilbestrol was interesting and is worthy of further study.
Two patients failed to mobilise stem cells in response to the initial high dose lenograstim and both of these had low CD34 counts in the peripheral blood following lenograstim prior to the first dose of melphalan. Both patients had prolonged neutropenia as would be expected, and this led to a protocol modification to ensure there was an adequate number of CD34 cells in peripheral blood prior to the administration of the first cycle of melphalan. Limitations here include the sample size and the fact that prostate cancer, like all cancer, is a heterogenous disease and many in this study had a particularly poor prognosis reflected in their short survival predicted by the MSKCC scoring system based on hemoglobin, PSA, LDH, alkaline phosphatase, albumin, Karnofsky performance status and current age. The current role of chemotherapy in the management of CRPC is taxane dominated; alkylating drugs have not been given much consideration in recent years. The rapid response in terms of CTCs, and pain control suggests that they may be useful though our approach was toxic.
The short duration of therapy and the ability to deliver docetaxel at a later date makes this approach more attractive and justifies its further exploration.
Legend for figures.
Figure1: study schema G1  G2  G3  G4  G1  G2  G3  G4  G1  G2  G3  G4  G1  G2  G3  G4   Infection   0%  8%  25%  0%  9%  0%  32%  0%  5%  9%  57%  0%  0%  7%  47%  7%   Malaise   25%  12%  0%  0%  59%  14%  4%  0%  38%  38%  10%  0%  53%  40%  0%  0%   Taste   0%  4%  0%  0%  9%  14%  0%  0%  19%  5%  0%  0%  13%  13%  0%  0%   Nausea   4%  0%  0%  0%  5%  5%  0%  0%  19%  0%  0%  0%  19%  0%  0%  0%   Vomiting   0%  0%  0%  0%  0%  0%  0%  0%  10%  0%  0%  0%  0%  0%  0%  0%   Constipation 4%   0%  0%  0%  5%  5%  0%  0%  14%  5%  0%  0%  0%  6%  0%  0%   Diarrhoea   21%  4%  0%  0%  14%  0%  0%  0%  15%  0%  0%  0%  6%  0%  0%  0%   Stomatitis   13%  13%  0%  0%  22%  13%  0%  0%  14%  10%  5%  0%  6%  19%  0%  0%   Anorexia   25%  4%  0%  0%  27%  9%  0%  0%  38%  14%  0%  0%  69%  12%  0%  0%   Alopecia   8%  0%  0%  0%  27%  5%  0%  0%  33%  14%  0%  0%  25%  12%  0%  0%   Dyspnoea   4%  0%  4%  0%  10%  0%  0%  0%  0%  11%  5%  0%  13%  6%  0%  0%   Neuropathy   0%  0%  0%  4%  0%  0%  0%  0%  0%  0%  0%  0%  0%  0%  0%  0% Research. Raw scores were standardised using a linear transformation, so that scores range from 0 to 100; a higher score represents a worse level of symptoms.
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